Jaka jest cena za Freeline Therapeutics Holdings plc (FRLN)

Cena za Freeline Therapeutics Holdings plc (FRLN) wynosi $6.48

Jaka jest kapitalizacja rynkowa dla Freeline Therapeutics Holdings plc (FRLN)

Kapitalizacja rynkowa dla Freeline Therapeutics Holdings plc (FRLN) wynosi $15.41M

Przychody Freeline Therapeutics Holdings plc (FRLN)

Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.

Rok	Przychody	Zmień
Za mało danych dla podanych dat.

Rok

Przychody

Zmień

Za mało danych dla podanych dat.

Firma	Przychody	Różnica w przychodach	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
CSL Limited CSL.AX	$15.70B	-	AU
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	$10.11B	-	BE

Firma

Przychody

Różnica w przychodach

Kraj